CFC numbers have shown to correlate with success of engraftment and speed of neutrophil recovery following cord blood (CB) transplantation. To investigate whether the number of Meg-CFC in a CB stem cell preparation might correlate with time to platelet engraftment, we evaluated the frequency of Meg-CFC among all CFC types in 134 CB, 21 adult bone marrow (BM) and 52 cytokine-mobilized peripheral blood (PB) stem cell preparations. The correlation of Meg-CFC with the total number of CFC and mixed cell-CFC was also assessed. The frequency of Meg-CFC was highest in CB and correlated significantly with total CFC numbers (mean 20.8%, correlation coefficient (r) 0.84, P = 0.0001) compared with Meg-CFC from mobilized PB (mean 13.1%, r = 0.29, P = 0.07) and BM (mean 4%, r = 0.39, P = 0.13). In addition, mixed-cell CFC numbers in CB were highly correlated with the total number of Meg-CFC (r = 0.7, P = 0.0001). No such correlations were found with mobilized PB or BM. We conclude that, based on the high degree of correlation between Meg-CFC and non-Meg-CFC numbers in CB, no additional information concerning time to platelet engraftment would be gained by routinely performing Meg-CFC assays in addition to non-Meg-CFC assays. The fact that CB Meg-CFC and mixed-cell CFC are strongly correlated suggests that CB Meg-CFC are more primitive than their counterparts in BM and PB and may reflect the number of stem cells in CB. In the past several years, there has been increasing use of stem cell preparations from cord blood (CB) instead of bone marrow (BM) for transplantation of unrelated recipients. Clinical reports of the effectiveness of CB for transplantation have now been published.
In the past several years, there has been increasing use of stem cell preparations from cord blood (CB) instead of bone marrow (BM) for transplantation of unrelated recipients. Clinical reports of the effectiveness of CB for transplantation have now been published. [1] [2] [3] [4] Despite the early enthusiasm for CB stem cell transplants, questions have arisen about the utility of CB for transplantation of adults due to the clear cell dose effect in terms of failure to engraft and time to neutrophil and platelet engraftment. 4 In fact, the delay in time to platelet engraftment has spurred investigations of methods to expand CB stem and progenitor cells with the goal of improving the rate of engraftment, as well as speeding the time to recovery of marrow function. [5] [6] [7] [8] [9] [10] As a result, there is considerable interest in defining the characteristics of CB stem cell preparations that would predict the likelihood of, and the time to, platelet engraftment.
With adult BM or cytokine-mobilized peripheral blood (PB) stem cell transplantation, the time to neutrophil engraftment correlates with the infused number of CD34 + cells per kg recipient body weight. [11] [12] [13] In addition, preliminary reports have shown a correlation between the number of megakaryocytic colony-forming cells (Meg-CFC) and time to platelet engraftment following PB transplants. [14] [15] [16] With CB transplants, there is a strong correlation between nucleated cell dose and rate of both neutrophil and platelet engraftment, and an even better correlation between the dose of progenitor cells, measured as the total number of granulocyte/macrophage (GM)-CFC, erythroid burst-forming cells (BFU-E) and mixed-cell CFC, and neutrophil engraftment. 17 No data have been presented relating CFC dose and time to platelet engraftment.
As the numbers and proliferative properties of the various progenitor cell types may be different in CB, BM and mobilized PB -and these differences might influence platelet recovery following transplantation -we have quantitated the proportion of Meg-CFC among all CFC types as well as their proliferative potential in CB, PB and BM. We have found that the proportion of Meg-CFC as well as their proliferative potential is highest in CB. Of interest, there was a strong correlation between the numbers of Meg-CFC and total numbers of CFC in CB -a correlation that was not found with BM or PB stem cell preparations. If one considers the practical aspects of performing routine CFC assays on all CB stem cell preparations, our findings indicate that adding Meg-CFC assays to the other CFC assays is unnecessary, and would provide little additional information related to platelet engraftment.
Materials and methods

Blood and bone marrow cell harvesting and processing
CB units were collected from the umbilical vein of freshly delivered placentas into blood collection bags containing CPD-A using procedures described previously. 18 The CB collection process and testing (including mother's) and informed consent procedures had been approved by the Institutional Review Boards of the New York Blood Center, Mt Sinai Medical Center and Brooklyn Hospital Center in New York City. Both BM and PB cells were obtained and tested with informed consent from the donors. The BM cells were anticoagulated with preservative-free heparin. PB cells were anticoagulated with ACD-A (Baxter, Deerfield, IL, USA). BM aspirates were obtained under local anesthesia from the posterior iliac crests of healthy donors, as well as patients with acute lymphoblastic or myelogenous leukemia thought to be in complete remission. PB was obtained from patients undergoing treatment for the following malignancies: brain tumor, non-Hodgkin lymphoma, Hodgkin's disease, breast cancer, multiple myeloma, cancer of the testis or ovarian cancer. Mobilization of stem cells into the PB was achieved by pretreating donors with granulocyte colony-stimulating factor (G-CSF). At the time of apheresis, patients showed no evidence of bone marrow involvement or other signs of disease and they had normal blood cell counts. CD34
+ cell numbers in BM and PB were determined by FACS analysis using a monoclonal FITCconjugated antibody (Coulter, Miami, FL, USA).
Progenitor cell assays
All samples were plated fresh and unmanipulated in plasma clots for assessment of Meg-CFC, or in methylcellulose (MTC) for assessment of GM-CFC, BFU-E and mixed-cell CFC within 24 h following harvest. CB was plated by volume (2 and 5 l/ml in plasma clots and in MTC; Aldrich Chemical, Milwaukee, WI, USA). BM and mobilized PB were plated by CD34
+ cell counts (300-1200 CD34 + cells/ml in plasma clots and 150 CD34 + cells/ml in MTC). As the number of nucleated cells (NC) in many of the PB and BM samples was very high and not associated with the number of CD34 + cells, samples were diluted over a range of 1:1 to 1:200 with Iscove's modified Dulbecco's medium (IMDM; Sigma, St Louis, MO, USA) and different concentrations of CD34 + cells were plated in a volume not exceeding 30 l (original volumes of the specimens were 0.1-5.0 l). Only plates that provided a sufficient number of colonies against a low background of NC were evaluated. The medium for the Meg-CFC assay consisted of IMDM containing 15% type AB Rh+ plasma, penicillinstreptomycin (100 U and 100 g/ml, respectively), sodium pyruvate 1 mm, vitamin solution 10 l/ml, non-essential amino acids 0.1 mm (all from Gibco, Gaithersburg, MD, USA), l-asparagine 2 g/ml, calcium chloride 2 mg/ml and bovine serum albumin (BSA) 0.15% wt/vol (all from Sigma). The growth factors, employed at their optimum concentration for colony growth, were recombinant human (rh) thrombopoietin (Tpo) 100 ng/ml (Kirin Pharmaceuticals, Tokyo, Japan), rh Flt-3 ligand 100 ng/ml and rh interleukin (IL)-11 10 ng/ml (both from Genetics Institute, Cambridge, MA, USA). To prevent clot lysis, the plasmin inhibitor aprotinin (Trasylol; Bayer, Kankakee, IL, USA) was added in a final concentration of 200 U/ml. The different specimens were mixed with 2 ml of this medium using a glass pipette and each plated into six wells of a 24-well plate, 330 l per well. After 14 days of incubation (37°C, 5% CO 2 , humidified air) the plasma clots were air-dried, fixed with a methanol/acetone solution at a ratio of 1:2, stored overnight at −20°C and doubly stained with FITCanti-CD41a (PharMingen, San Diego, CA, USA) and propidium iodide (Sigma) (final concentration 500 ng/ml). For optimal fluorescence, the original anti-CD41a had been diluted 1:50-1:100. Meg colonies were evaluated by fluorescence microscopy (mercury lamp, incident-light filter wavelength pass 450-490 nm) and total numbers of colonies, large colonies (Ͼ50 cells) and small colonies (Ͻ50 cells) scored.
For assessment of GM colonies, erythroid bursts and mixed-cell colonies, a standard MTC assay was used. 17 Each 1 ml Petri dish (Becton Dickinson, Franklin Lakes, NJ, USA) contained 30% (vol/vol) fetal bovine serum (Gemini Bioproducts, Calabasas, CA, USA), BSA 0.9% wt/vol (Sigma), ␤-mercaptoethanol 7.5 × 10 −5 mol/l, penicillin-streptomycin 100 U and 100 g/ml, respectively, lglutamine 2 mm (all from Gibco), and MTC 0.8% wt/vol in IMDM. To stimulate colony growth, the following growth factors were added at their previously determined optimal concentrations: rh IL-3 10 U/ml, rh stem cell factor (SCF) 5 ng/ml, rh GM-CSF 10 ng/ml, rh G-CSF 10 ng/ml and rh erythropoietin (Epo) 20 ng/ml (all from Amgen, Thousand Oaks, CA, USA). After 14 days of incubation (37°C, 5% CO 2 , 5% O 2 in air), colonies were counted using an inverted light microscope. The correlation coefficient (r) between Meg colonies and all other colony types was calculated by Pearson statistics using SAS software.
Results
Proliferative potential of megakaryocytic progenitor cells
Rh Flt-3 ligand, rh Tpo and rh IL-11 were chosen as the most suitable cytokine combination to support Meg colony growth in plasma clots. This combination yielded maximum numbers of Meg colonies against a low background of non-Meg colonies. 19 Colony size was used to assess proliferative response. Of the 134 CB samples cultured, 109 (81%) showed a higher proportion of large Meg colonies than small Meg colonies (mean, 64%; median, 65%). In contrast, only 17% (nine of 52) of the cultures of mobilized PB cells and 0% (0 of 21) of the BM cell cultures showed a higher proportion of large Meg colonies than small. The mean percent of small Meg colonies in cultures of mobilized PB was 72% (median, 76%) and 93% (median, 100%) in BM cultures.
Frequency and correlation of Meg-CFC numbers to total CFC numbers
The frequency and correlation of Meg-CFC numbers to total CFC numbers, as well as the correlation between the numbers of Meg-CFC and mixed-cell CFC, were assessed for all stem cell sources. All 134 samples of CB, 40 out of 52 samples of PB and 16 out of 21 samples of BM were evaluated in parallel for the total numbers of non-Meg-CFC and Meg-CFC. Fifteen of the 16 PB samples were evaluable for mixed-cell CFC content (Table 1) . Meg-CFC from CB showed the highest frequency among total CFC numbers (mean, 20.8%; median, 20.5%; range, 4-46%; s.e.m. 0.09%) compared to Meg-CFC from mobilized PB (mean, 13.1%; median, 8%; range, 0.4-75%; s.e.m. 9.2%) and BM (mean, 4%; median, 3%; range, 0-6%; s.e.m. 2.7%) (Figure 1 ).
For cultures of PB or BM, plating by CD34 + cell counts over a range of concentrations avoided misreading because of overcrowding or underplating dishes and was superior to plating by NC counts or by volume. For these two stem cell sources, the number of NC and CD34 + cells were not well correlated; thus, individual samples with high CD34 + cell numbers might not have been enriched for CFC. In addition, depending on the window chosen, some cells that had low CD34 expression could still generate colonies so that the number of CFC found in some of the samples was greater than the number of CD34 + originally plated ( Figure  2 ). For CB, no routine assessment of CD34 + cell numbers was performed as engraftment is known to correlate strongly with NC and, especially, CFC counts. 4, 17 Plating of CB in two standard volumes was found to be sufficient for reliable assessment.
Meg-CFC numbers in CB correlated significantly with total CFC numbers (r = 0.84; P = 0.0001), whereas no such correlation was seen with mobilized PB or BM (r = 0.29; P = 0.07 for mobilized PB and r = 0.39; P = 0.13 for BM) (Figure 2) . To determine the possible effect of sample size on the statistical analysis, the data from consecutive sets of Table 1 The numbers of CFC (Meg-CFC, mixed-cell CFC, BFU-E and GM-CFC) were assessed in the three stem cell sources: cord blood (n = 134), mobilized peripheral blood (n = 40) and bone marrow (n = 15)
Cord blood
Mobilized In addition, in CB, mixed-cell CFC numbers were highly correlated with the total numbers of Meg-CFC (r = 0.70; P = 0.0001). Mixed-cell CFC in mobilized PB and BM showed neither a statistically significant correlation with total Meg-CFC numbers nor with the numbers of Meg-CFC giving rise to large colonies. The values in PB were r = 0.49 (P = 0.06) for the correlation between total CFC numbers and all Meg-CFC. For BM, the value was r = 0.23 (P = 0.41). The numbers of each CFC type in CB, PB and BM are shown as the median, mean (± s.e.m.) and range in Table 1 . 
Bone Marrow Transplantation
Discussion
An outgrowth of the Placental/CB Program of the New York Blood Center was the early decision to quantitate the number of CFC in all processed CB stem cell units in order to assess the functional capacity of the units. This decision was made because of the recognized differences in CD34 expression and correlation with function in hematopoietic tissues of different ontogenetic stages. [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] Previously, the Placental/CB Program reported on the correlation between nucleated cell dose and the success and speed of both neutrophil and platelet engraftment following 562 unrelated CB stem cell transplants. 4 The analysis showed a clear cell dose effect for both success of engraftment and speed of both neutrophil and platelet recovery. Thus, the time to neutrophil engraftment (defined as the time to achieve and maintain a neutrophil count of 500/l) overall was 28 days, but was reduced to a median of 18 days in patients who had received an NC dose of 100 × 10 6 /kg. For platelets, the time to engraftment (defined as the time to achieve a platelet count of 50 000/l without benefit of platelet transfusions) overall was 90 days, but was reduced to 65 days in those patients who received a NC dose of at least 50 × 10 6 /kg. However, we have also provided preliminary evidence indicating that the number of CFC transplanted per kg recipient body weight correlated even more strongly with these clinical outcomes. 17 Given concerns over the time to platelet engraftment in this setting, we undertook the routine assay of Meg-CFC on more than 130 consecutively collected CB samples and characterized both their numbers and proliferative capacity. Our intent was to correlate their numbers in the grafts with the time to platelet engraftment since well-characterized CB stem cell preparations were used for transplantation. Because Meg-CFC numbers have been reported to correlate with time to platelet recovery following PB transplantation, [14] [15] [16] we compared the results obtained with CB with adult BM and cytokine-mobilized PB.
The results show clear differences in the properties of Meg-CFC from these different stem cell sources. First, the proportion of Meg-CFC among all CFC was much higher in CB than in BM or cytokine-mobilized PB. Second, the vast majority of CB samples, in contrast to PB and BM, contained a high number of Meg-CFC that gave rise to large (р50 cells) colonies. Many of these colonies contained several thousand cells. In contrast, only a few of the PB and none of the BM samples contained Meg-CFC that gave rise to a majority of large colonies and the large colonies that did form only rarely exceeded 100 cells. The predominance of extremely large Meg colonies is consistent with previously published reports indicating a greater proliferative potential of CFC from CB than from other stem cell sources. 24, 27, [31] [32] [33] [34] [35] [36] [37] [38] [39] Meg-CFC and other progenitor cell types from different hematopoietic tissues display different patterns of responsiveness to various cytokines. The differences in responsiveness may depend on the stage of maturation, expression of surface receptors and ontogenetic stage. 10, 25, 29, 31, [40] [41] [42] [43] Furthermore, Meg colony growth and the properties of Meg-CFC vary not only between stem cell sources, but also between CD34 + subpopulations. When CD34 + cells from CB were separated by CD41 selection, optimal growth of Meg colonies in cultures of CD34 + CD41 − cells required the combination of Tpo and IL-3, as opposed to Tpo alone with cultures of CD34 + CD41 + cells. 37 As Meg-CFC could be present in phenotypically different subgroups of progenitor cells from the different hematopoietic tissues, we used unmanipulated CB, PB and BM for the evaluation of Meg-CFC and excluded the preselection of progenitors by surface markers.
We found that the relative frequency of Meg-CFC was highest in CB, followed by PB and BM (Figure 1 , Table 1 ). Although the frequencies of Meg-CFC in individual CB samples varied widely, there was still a statistically significant correlation between the numbers of Meg-CFC and total CFC in each sample as well as between Meg-CFC and mixed-cell CFC. No significant correlations were found for the various types of CFC in PB and BM (Figure 2 ).
Mixed-cell CFC generate complex colonies containing multiple lineages, presumably reflecting an early stage of progenitor cell development. 44, 45 The greater percentage Meg-CFC in CB that give raise to large colonies, combined with a highly significant correlation of Meg-CFC with mixed-cell CFC, is consistent with the conclusion that CB contains more primitive cells than PB or BM. Other than in PB and BM, where the numbers of CD34 + cells are believed to reflect the numbers of stem cells, in CB the number of CFC may be most reflective of stem cell dose. Given the extremely close correlation between Meg-CFC and all other CFC in CB, an additional evaluation of the content of Meg-CFC in each processed CB stem cell unit as a routine procedure is not warranted in the pre-transplant investigations of hematopoietic potential of such units. Meg CFC assays of CB units are unlikely to provide additional useful information with regard to clinical outcomes of CB transplantation, such as engraftment or time to platelet recovery.
